These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38915617)

  • 1. GABA production induced by imipridones is a targetable and imageable metabolic alteration in diffuse midline gliomas.
    Batsios G; Udutha S; Taglang C; Gillespie AM; Lau B; Ji S; Phoenix T; Mueller S; Venneti S; Koschmann C; Viswanath P
    bioRxiv; 2024 Jun; ():. PubMed ID: 38915617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas.
    Przystal JM; Cianciolo Cosentino C; Yadavilli S; Zhang J; Laternser S; Bonner ER; Prasad R; Dawood AA; Lobeto N; Chin Chong W; Biery MC; Myers C; Olson JM; Panditharatna E; Kritzer B; Mourabit S; Vitanza NA; Filbin MG; de Iuliis GN; Dun MD; Koschmann C; Cain JE; Grotzer MA; Waszak SM; Mueller S; Nazarian J
    Neuro Oncol; 2022 Sep; 24(9):1438-1451. PubMed ID: 35157764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine pre-treatment impairs the anti-cancer effect of integrated stress response- and TRAIL pathway-inducing ONC201, ONC206 and ONC212 imipridones in pancreatic, colorectal cancer but not DMG cells.
    Zhang Y; Tapinos N; Lulla R; El-Deiry WS
    Am J Cancer Res; 2024; 14(5):2453-2464. PubMed ID: 38859853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
    Borsuk R; Zhou L; Chang WI; Zhang Y; Sharma A; Prabhu VV; Tapinos N; Lulla RR; El-Deiry WS
    Am J Cancer Res; 2021; 11(9):4607-4623. PubMed ID: 34659909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma.
    Ishida CT; Zhang Y; Bianchetti E; Shu C; Nguyen TTT; Kleiner G; Sanchez-Quintero MJ; Quinzii CM; Westhoff MA; Karpel-Massler G; Prabhu VV; Allen JE; Siegelin MD
    Clin Cancer Res; 2018 Nov; 24(21):5392-5406. PubMed ID: 30037819
    [No Abstract]   [Full Text] [Related]  

  • 6. Novel combination of imipridones and histone deacetylase inhibitors demonstrate cytotoxic effect through integrated stress response in pediatric solid tumors.
    Chang WI; Honeyman JN; Zhang J; Lin C; Sharma A; Zhou L; Oliveira J; Tapinos N; Lulla RR; Prabhu VV; El-Deiry WS
    Am J Cancer Res; 2023; 13(12):6241-6255. PubMed ID: 38187038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroendocrine Prostate Cancer Drivers SOX2 and BRN2 Confer Differential Responses to Imipridones ONC201, ONC206, and ONC212 in Prostate Cancer Cell Lines.
    Purcell C; Srinivasan PR; Pinho-Schwermann M; MacDonald WJ; Ding E; El-Deiry WS
    bioRxiv; 2024 Aug; ():. PubMed ID: 39257809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.
    Wagner J; Kline CL; Ralff MD; Lev A; Lulla A; Zhou L; Olson GL; Nallaganchu BR; Benes CH; Allen JE; Prabhu VV; Stogniew M; Oster W; El-Deiry WS
    Cell Cycle; 2017 Oct; 16(19):1790-1799. PubMed ID: 28489985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ONC206 targeting ClpP induces mitochondrial dysfunction and protective autophagy in hepatocellular carcinoma cells.
    Cao J; Cao F; Wang C; Jiao Z; You Y; Wang X; Zhao W
    Neoplasia; 2024 Sep; 55():101015. PubMed ID: 38944913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
    Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
    Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells.
    Bonner ER; Waszak SM; Grotzer MA; Mueller S; Nazarian J
    Neuro Oncol; 2021 Apr; 23(4):542-556. PubMed ID: 33336683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered.
    Jackson ER; Persson ML; Fish CJ; Findlay IJ; Mueller S; Nazarian J; Hulleman E; van der Lugt J; Duchatel RJ; Dun MD
    Neuro Oncol; 2024 May; 26(Supplement_2):S136-S154. PubMed ID: 37589388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ONC206 has anti-tumorigenic effects in human ovarian cancer cells and in a transgenic mouse model of high-grade serous ovarian cancer.
    Tucker K; Yin Y; Staley SA; Zhao Z; Fang Z; Fan Y; Zhang X; Suo H; Sun W; Prabhu VV; Allen JE; Zhou C; Bae-Jump VL
    Am J Cancer Res; 2022; 12(2):521-536. PubMed ID: 35261784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma.
    Jackson ER; Duchatel RJ; Staudt DE; Persson ML; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara WSN; Le Grand M; Kearney PS; Douglas AM; Findlay IJ; Germon ZP; McEwen HP; Beitaki TS; Patabendige A; Skerrett-Byrne DA; Nixon B; Smith ND; Day B; Manoharan N; Nagabushan S; Hansford JR; Govender D; McCowage GB; Firestein R; Howlett M; Endersby R; Gottardo NG; Alvaro F; Waszak SM; Larsen MR; Colino-Sanguino Y; Valdés-Mora F; Rakotomalala A; Meignan S; Pasquier E; Andre N; Hulleman E; Eisenstat DD; Vitanza NA; Nazarian J; Koschmann C; Mueller S; Cain JE; Dun MD
    Cancer Res; 2023 May; 83(14):2421-37. PubMed ID: 37145169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma.
    Jackson ER; Duchatel RJ; Staudt DE; Persson ML; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara WSN; Grand ML; Kearney PS; Douglas AM; Findlay IJ; Germon ZP; McEwen HP; Beitaki TS; Patabendige A; Skerrett-Byrne DA; Nixon B; Smith ND; Day B; Manoharan N; Nagabushan S; Hansford JR; Govender D; McCowage GB; Firestein R; Howlett M; Endersby R; Gottardo NG; Alvaro F; Waszak SM; Larsen MR; Colino-Sanguino Y; Valdes-Mora F; Rakotomalala A; Meignan S; Pasquier E; André N; Hulleman E; Eisenstat DD; Vitanza NA; Nazarian J; Koschmann C; Mueller S; Cain JE; Dun MD
    Cancer Res; 2023 May; ():OF1-OF17. PubMed ID: 37195023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
    Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
    Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma.
    Chattopadhyay C; Roszik J; Bhattacharya R; Alauddin M; Mahmud I; Yadugiri S; Ali MM; Khan FS; Prabhu VV; Lorenzi PL; Wei B; Burton E; Morey RR; Lazcano R; Davies MA; Patel SP; Grimm EA
    Br J Cancer; 2024 Dec; 131(11):1846-1857. PubMed ID: 39394450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric diffuse midline glioma H3K27- altered: A complex clinical and biological landscape behind a neatly defined tumor type.
    Vallero SG; Bertero L; Morana G; Sciortino P; Bertin D; Mussano A; Ricci FS; Peretta P; Fagioli F
    Front Oncol; 2022; 12():1082062. PubMed ID: 36727064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venetoclax Cooperates with Ionizing Radiation to Attenuate Diffuse Midline Glioma Tumor Growth.
    Madhavan K; Balakrishnan I; Lakshmanachetty S; Pierce A; Sanford B; Fosmire S; Elajaili HB; Walker F; Wang D; Nozik ES; Mitra SS; Dahl NA; Vibhakar R; Venkataraman S
    Clin Cancer Res; 2022 Jun; 28(11):2409-2424. PubMed ID: 35344040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer.
    Paraghamian SE; Qiu J; Hawkins GM; Zhao Z; Sun W; Fan Y; Zhang X; Suo H; Hao T; Prabhu VV; Allen JE; Zhou C; Bae-Jump V
    Cancer Biol Ther; 2023 Dec; 24(1):2202104. PubMed ID: 37069726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.